Inclusion Criteria:

1. Confirmed diagnosis of previously untreated nodular or diffuse mantle cell lymphoma and their blastoid cytologic variant.
2. ECOG Performance status of 0, 1, or 2.
3. Serum bilirubin <1.5mg/dl and serum creatinine < 2.0 mg/dl within 14 dyas before enrollment (unless higher levels are due to lymphoma)
4. Platelet count>100,000/mm^3 and absolute neutrophil count (ANC)>1,000/mm^3 within 14 days before enrollment (unless due to lymphoma).
5. Cardiac ejection fraction >/= 50% by ECHO or MUGA.
6. Age 18 years to 79 years.
7. Patients must be willing to receive transfusions of blood products.
8. Voluntary written IRB-approved informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
9. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
10. Male subject agrees to use an acceptable method for contraception for the duration of the study.

Exclusion Criteria:

1. HIV infection.
2. CNS involvement.
3. Co-morbid medical or psychiatric illnesses that preclude treatment with intense dose chemotherapy.
4. Concurrent or previous malignancy with < 90% probability of survival at 5 years.
5. Patient has >/= Grade 2 peripheral neuropathy within 14 days before enrollment.
6. Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
7. Patient has hypersensitivity to boron or mannitol.
8. Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
9. Patient has received other investigational drugs within 14 days before enrollment.
10. Diagnosed or treated for another malignancy ,that has a less than 90% chance of survival at 5 years.
11. Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.